Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva

Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva

Abstract Fibrodysplasia ossificans progressive (FOP) is an ultra-rare genetic disorder that is caused by a mutation in the ACVR1 gene and provokes severe heterotopic ossification. Since flares of the disease are associated with inflammation, it is assumed that JAK inhibitors can control active FOP d...

Full description

Bibliographic Details
Main Authors: Irina P. Nikishina, Svetlana V. Arsenyeva, Valeria G. Matkava, Alia N. Arefieva, Mariya I. Kaleda, Alexandr V. Smirnov, Leonid M. Blank, Mikhail M. Kostik
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Fibrodysplasia ossificans progressiva
FOP
Heterotopic ossification
Tofacitinib
Autoinflammation
Spondyloarthritis-like disease
Online Access:https://doi.org/10.1186/s12969-023-00856-1

Internet

https://doi.org/10.1186/s12969-023-00856-1

Similar Items